MSTN and proximal spinal muscular atrophy: Such a design would enable the evaluation of treatment efficacy across the diverse clinical spectrum of SMA, while also facilitating subgroup analyses to identify those most likely to benefit from myostatin inhibition or other adjunctive approaches.